anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A mercapto-carboxylic acid is neutralized with solid ammonium carbonate or bicarbonate or a solid mixture of these salts, and into the mixture there is incorporated either simultaneously or subsequently a solid alkali which is substantially more basic than the ammonium salts and which, when dissolved in water at 20 DEG C. to form a 1 per cent by weight solution, gives a pH greater than 8 but less than 13, the final product being a solid composition soluble in water to form a hair-relaxing solution.  The preferred mercapto-carboxylic acid is thioglycollic acid.  Suitable alkaline compounds more basic than the ammonium salts are sodium and potassium carbonates and the tri-alkali metal phosphates. Commercial ammonium carbonate may be used to neutralize the mercapto carboxylic acid.  In an example 20 g. of 95 per cent thioglycollic acid is neutralized with 20 g. of powdered commercial ammonium carbonate and stirred until evolution of carbon dioxide ceases, whereafter 24 g. of sodium carbonate is added and the whole is mixed to form a dry-free-flowing powder. Specifications 589,956, 721,831 and 748,858 [Group IV(b)] are referred to.
BACKGROUND: Inhibin A and N6-methyladenosine methylation modifications participate in oral squamous cell carcinoma development. However, the N6-methyladenosine modification of Inhibin A in oral squamous cell carcinoma has not been revealed. This study reveals a key gene "Inhibin A" that may affect the tumorigenesis of oral squamous cell carcinoma and its molecular mechanisms on N6-methyladenosine methyltransferase KIAA1429-mediated N6-methyladenosine methylation modification.
METHODS: Bioinformatics analysis and quantitative real-time polymerase chain reaction identified the potential regulatory genes in oral squamous cell carcinoma. We examined the changes in the proliferation (Cell Counting Kit-8 assay), migration (transwell migration assay), and invasion (transwell invasion assays) of oral squamous cell carcinoma cells. We performed a xenograft tumor experiment to validate the role of Inhibin A in oral squamous cell carcinoma in vivo. The interactions between Inhibin A and KIAA1429 were analyzed using bioinformatics, methylated RNA immunoprecipitation-qPCR, quantitative real-time polymerase chain reaction, and Western blotting experiments.
RESULTS: Inhibin A had the highest expression in patients with oral squamous cell carcinoma. Inhibin A silencing impaired the ability of oral squamous cell carcinoma cells to proliferate, migrate, and invade, as well as limited the tumorous growth of oral squamous cell carcinoma cells in vivo. Bioinformatics analysis showed that Inhibin A expression positively interacted with KIAA1429 expression in The Cancer Genome Atlas database. The levels were also upregulated in our clinical samples. Furthermore, KIAA1429 silencing repressed the N6-methyladenosine level of Inhibin A in oral squamous cell carcinoma.
CONCLUSIONS: Inhibin A promotes the tumorigenesis of oral squamous cell carcinoma by KIAA1429-mediated N6-methyladenosine modification. This study adds to our current knowledge of the molecular mechanisms underlying oral squamous cell carcinoma malignancy.
Proof-of-concept study, multicenter, randomized, double-blind, parallel-group, placebo-controlled study designed to evaluate the safety and efficacy of a transdermal ketoprofen patch with CHADD heat versus a placebo patch with dummy heat in patients with mild to moderate pain associated with osteoarthritis of the knee. After screening, patients discontinue all analgesic medication (except ≤325 mg aspirin daily for cardioprotective purposes). Patients selected a target knee (right or left), and all efficacy evaluations were completed with respect to this target knee. After discontinuing analgesics for at least 48 hours, and when the average pain intensity over the previous 24 hours for the target knee was ≥40 mm using a 100 mm visual analog scale (VAS), patients were randomized in a 1:1 fashion to receive treatment with either the transdermal ketoprofen patch with CHADD heat or the placebo patch with dummy heat. Patients treated the target knee each night for 12 hours (± 1 hour) for 4 weeks. Patients returned to the study site every 7 days (± 1 day) for study evaluations. Throughout the study, patients were allowed to take up to 2000 mg acetaminophen per day as rescue medication; however, rescue medication was not allowed within the 48 hours prior to efficacy evaluations.
Estimated total blood loss, measured using the formula described by Nadler. A difference in estimated blood loss greater than or equal to 245 ml will be considered clinically relevant.
PROBLEM TO BE SOLVED: To obtain a dentifrice composition excellent in removing effects on halitosis and capable of effectively suppressing the halitosis by making the composition include hydroxyapatite and an extract of a plant containing a flavonoid therein. SOLUTION: This composition is obtained by including (A) hydroxyapatite represented by the formula Ca10 (PO4 )6 (OH)2 and (B) an extract of a plant containing a flavonoid (Scutellariae Radix, Phellodendri Cortex, Aurantii Nobilis Pericarpium, an eggplant, etc.). In the composition, 0.1-60 wt.% ingredient and 0.01-30 wt.% ingredient B are preferably contained. A method for extracting and collecting the ingredient B from the flavonoid-containing plant with an extracting solvent, e.g. water, an organic solvent or a mixed solvent of water with the organic solvent, a method for extracting and collecting the ingredient B by steam distillation, etc., are cited as the method for obtaining the ingredient B. In the composition, a polishing agent, a humectant, a surfactant, a binder, a sweetener, etc., can be contained as other ingredients.
The worldwide HIV/AIDS epidemic may only be controlled through a safe and effective vaccine that will prevent HIV infection. DNA vaccines are inexpensive to construct, easily produced in large quantities, and stable for long periods of time. Recombinant modified vaccinia Ankara vaccines have been shown to be safe in humans, and immunogenicity after administration of both vaccines has been encouraging. When used together, a more robust immunologic response was associated with DNA HIV vaccine administration followed by modified vaccinia vaccine administration, compared to using either DNA or vaccinia vaccine alone. This study will evaluate the safety and immunogenicity of an experimental DNA HIV vaccine prime, pGA/JS7, followed by a similarly structured modified vaccinia boost, MVA/HIV62, in HIV uninfected adults. Participants in this study will be recruited only in the United States.

This study will be divided into 2 parts. Each participant will be involved with their part of study for 1 year. Participants in Part 1 will be randomly assigned to one of two different vaccination groups. Group 1A participants will be randomly assigned to receive either placebo or 2 lower doses of the DNA HIV vaccine (DNA) at study entry and Month 2, followed by 2 lower doses of the modified vaccinia vaccine (MVA) at Months 4 and 6. Group 1B will not enroll until safety and immunogenicity data from Group 1A have been evaluated. Group 1B participants will receive either placebo or two higher doses of DNA at study entry and Month 2, followed by two higher doses of MVA at Months 4 and 6.

Enrollment into Part 2 will begin only after safety data from Part 1 are reviewed. In Part 2, participants will be randomly assigned to one of two different vaccination groups. Within each group, participants will be randomly assigned to receive some series of vaccines or placebo. Group 2A participants will receive either placebo or the maximum tolerated dose (MTD) from Part 1 of DNA at study entry and MTD of MVA at Months 2 and 6. Group 2B participants will receive MTD of MVA at study entry and Months 2 and 6.

There will be 12 study visits over 12 months for Groups 1 and 2. There will be 11 study visits over 12 months for Groups 3 and 4. Medication history, a physical exam, an interview, HIV and pregnancy prevention counseling, and adverse events reporting will occur at all visits. Blood and urine collection and an electrocardiogram (ECG) will occur at selected visits.
In this arm, only the regenerative treatment of XCM® intim of the company Mucosa Innovations will be used. The route of administration would be vulvo-vaginal. The dose applied would be 2 ml of total product every 12 hours. The total duration of treatment would be 36 months.
Breast cancer is one of the leading causes of cancer death for women in Taiwan. We have recently demonstrated that combination of paclitaxel and cisplatin, at conventional doses, is highly effective in the treatment of breast cancer. However, the acute and cumulative toxicities of paclitaxel have been troublesome to a significant portion of the patients. Several lines of evidence suggested that weekly paclitaxel, at a much lower dose range of 40 to 50 mg/m2 per week, may be as effective as that of the conventional doses of paclitaxel (80 to 90 mg/m2 per week) for patients with metastatic ovarian and lung cancers. The low-dose regimen of paclitaxel may significantly improve the compliance of the patients. This open-label phase II trial is designed to test this hypothesis.
The invention belongs to the technical field of medicine, and relates to an oxazine compound and medical application thereof. The oxazine compound and pharmaceutically-applicable salt thereof formed by the addition with acid can be used as a platelet aggregation inhibitor. The structural general formula is shown in the specification. In the structural formula I or II or III or IV or V or VI, R can be independently selected from H, C1-C4 alkyl and benzyl, or substituted or unsubstituted aryl. The synthesis method of the compound provided by the invention is simple and is applicable to industrial production; the compound is more stable in comparison with natural analogs; and biological activity tests show that the compound has analgesic, antiphlogistic and anticoagulant activities. Thus, the compound is a platelet aggregation inhibitor.
Metabolic reprogramming plays a critical role in hepatocarcinogenesis. However, the mechanisms regulating metabolic reprogramming in primary liver cancer (PLC) are unknown. Differentially expressed miRNAs between PLC and normal tissues were identified using bioinformatic analysis. RT-qPCR was used to determine miR-10b-5p and SCL38A2 expression levels. IHC, WB, and TUNEL assays were used to assess the proliferation and apoptosis of the tissues. The proliferation, migration, invasion, and apoptosis of PLC cells were determined using the CCK-8 assay, Transwell assay, and flow cytometry. The interaction between miR-10b-5p and SLC38A2 was determined using dual-luciferase reporter assay. A PLC xenograft model in BALB/c nude mice was established, and tumorigenicity and SLC38A2 expression were estimated. Finally, liquid chromatography - mass spectrometry (LC-MS) untargeted metabolomics was used to analyze the metabolic profiles of xenograft PLC tissues in nude mice. miR-10b-5p was a key molecule in the regulation of PLC. Compared with para-carcinoma tissues, miR-10b-5p expression was increased in tumor tissues. miR-10b-5p facilitated proliferation, migration, and invasion of PLC cells. Mechanistically, miR-10b-5p targeted SLC38A2 to promote PLC tumor growth. Additionally, miR-10b-5p altered the metabolic features of PLC in vivo. Overexpression of miR-10b-5p resulted in remarkably higher amounts of lumichrome, folic acid, octanoylcarnitine, and Beta-Nicotinamide adenine dinucleotide, but lower levels of 2-methylpropanal, glycyl-leucine, and 2-hydroxycaproic acid. miR-10b-5p facilitates the metabolic reprogramming of PLC by targeting SLC38A2, which ultimately boosts the proliferation, migration, and invasion of PLC cells. Therefore, miR-10b-5p and SLC38A2 are potential targets for PLC diagnosis and treatment.
Among the methods for cognitive control of pain, the suggestions for analgesia-direct or indirect-have been widely and successfully used in experimental and clinical trials. The primary aim of this study was to contribute to the debate about the difference in the effectiveness of indirect and direct suggestions for the management of experimental pain in the ordinary state of consciousness. The secondary aim of the study was to ascertain the role of hypnotizability and expectation of pain relief in the suggestions' effect. A sample of 65 healthy participants with different levels of direct (Harvard Group Scale of Hypnotic Susceptibility: A score) and indirect suggestibility level (Alman-Wexler Indirect Hypnotic Susceptibility Scale score) and different levels of declared expectation of pain relief was submitted to direct and indirect suggestions for analgesia during cold pressure test. The results showed that both direct and indirect suggestions increase the threshold of experimental pain and that the expectation of pain relief is relevant only to the effect of direct suggestions. PERSPECTIVE: Although the reported findings cannot be extended to clinical pain, they suggest that indirect suggestions can be effective independently from the expectation of pain relief, thus evading the possible negative effects of traits such as catastrophism or reactance. Thus, indirect suggestions should be preferred in clinical contexts.
FIELD: medicine. SUBSTANCE: method involves applying anesthesia by intraperitoneally injecting calipsol at a dose of 50 mg/kg. Anesthesia state being achieved, the sixth and seventh cervical vertebrae are identified based on anatomical symptoms. Sterile needle, its diameter corresponding to spinal cord one, is introduced in perpendicular to spinal canal axis into the spinal cord until downfall impression occurs. Two min later the needle is pulled off. EFFECT: controllable scale of the vertebrocerebrospinal trauma; minimum traumatic affection of the surrounding tissues.
BACKGROUND: This study aimed to describe a case of rhabdomyolysis and acute kidney injury potentiated by a drug-drug interaction (DDI) between cyclosporine, leflunomide, and rosuvastatin in a kidney transplant recipient.
CASE SUMMARY: A 74-year-old male with end-stage kidney disease secondary to type 2 diabetes mellitus and hypertension received a deceased by cardiac death kidney transplant. The patient's medical history included coronary artery disease and hyperlipidemia for which he was receiving rosuvastatin 40 mg daily. Five months after transplant, the patient developed BK viremia, which required multiple changes in immunosuppression and resulted in the initiation of leflunomide and cyclosporine modified. The patient used multiple pharmacies and coupon cards that delayed the identification of the DDIs between leflunomide, cyclosporine, and rosuvastatin. Approximately, 13 months after transplant, the biopsy report of the patient's allograft kidney showed acute cellular rejection Banff IB, hypertensive changes, and transplant glomerulopathy. This prompted the patient to receive a 3-day course of methylprednisolone 250 mg intravenous at the outpatient infusion center. Two weeks later, the patient presented to the transplant clinic with lightheadedness, dizziness, weakness, fatigue, bilateral eye drainage, and a decrease in appetite and was admitted to the hospital for further workup. On admission, creatine kinase was 2080 IU/L with myoglobin of 7601 ng/mL. The patient's diagnosis was statin myopathy with possible rhabdomyolysis acute kidney injury. Likely contributing factors included cyclosporine, leflunomide, and rosuvastatin DDI and administration of high-dose methylprednisolone.
PRACTICE IMPLICATIONS: This case demonstrates the importance of pharmacist involvement throughout all phases of care in a kidney transplant recipient.
Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose \~ 16% of their presurgery body weight.
A single-center feasibility study performed in patients undergoing a planned cardiac catheterization. This study investigated the feasibility of the NeuroTronik CANS Therapy™ System to improve acute hemodynamics. Purpose-built stimulation catheters were percutaneously inserted into an upper venous structure near the heart via right femoral vein and or left subclavian vein access using standard introducers and techniques. Subjects were instrumented with left ventricular and femoral artery catheters for pressure measurement and stimulated for approximately 60 minutes. Baseline hemodynamic measures were collected before stimulation and compared to measured values during stimulation. Following completion of the protocol, all in-dwelling equipment and catheters were removed.
The invention provides medicinal liquor for treating duodenal ulcer. The medicinal liquor is characterized by being prepared from the following raw materials in parts by weight: 200-300 parts of Chinese dates, 200-300 parts of Chinese yam, 200-300 parts of barbary wolfberry fruit, 100-200 parts of hawthorn, 100-200 parts of fructus amomi, 100-200 parts of malt, 30-50 parts of dried ginger, 30-50 parts of inner membrane of chicken gizzard, 80-100 parts of fried dried tangerine peel and 2000-3000 parts of white spirit. During preparation, the Chinese dates, Chinese yam, barbary wolfberry fruit, hawthorn, fructus amomi, dried ginger, malt, inner membrane of chicken gizzard and fried dried tangerine peel are dried and mashed and are put into an earthen pot, the white spirit is added and heated to 70 DEG C, hot dipping is carried out for 30 minutes, and the liquor is filtered to remove dregs, thus obtaining the medicinal liquor. When in use, about 20-30ml of the medicinal liquor is taken each time and is orally taken twice a day. One course of treatment lasts two months. The medicinal liquor is reasonable in compatibility, is convenient to use, strengthens the spleen and stomach, helps digestion and relieves dyspepsia and warms the spleen and stomach to dispel cold, can effectively treat duodenal ulcer, can be taken for a long time, and does not have any side effect.
BACKGROUND: HIV-infected persons demonstrate notable disturbances in their intestinal microbiota; however, the impact of intestinal microbiota on HIV susceptibility in men who have sex with men (MSM), as well as the effects of HIV and antiretroviral therapy (ART) on their gut microbiota, remains under active study. Thus, our research focuses on clarifying the distinctions in intestinal microbiota composition among uninfected MSM and non-MSM healthy controls, investigating the alterations in early-stage intestinal microbial communities following HIV infection, and assessing how ART affects the intestinal microbiota.
METHODS: This study enrolled four participant groups: uninfected MSM, Recent HIV-1 infection (RHI) MSM, MSM on ART, and non-MSM healthy controls, with 30 individuals in each group. We utilized 16S ribosomal DNA (16S rDNA) amplicon sequencing to analyze fecal microbiota and employed Luminex multiplex assays to measure plasma markers for microbial translocation (LBP, sCD14) and the inflammatory marker CRP.
FINDINGS: Comparing uninfected MSM to non-MSM healthy controls, no substantial variances were observed in α and β diversity. Uninfected MSM had higher average relative abundances of Bacteroidetes, Prevotella, and Alloprevotella, while Bacteroides, Firmicutes, and Faecalibacterium had lower average relative abundances. MSM on ART had lower intestinal microbiota diversity than RHI MSM and uninfected MSM. In MSM on ART, Megasphaera and Fusobacterium increased, while Faecalibacterium and Roseburia decreased at genus level. Additionally, treatment with a non-nucleoside reverse transcriptase inhibitor (NNRTI) led to significant alterations in intestinal microbiota diversity and composition compared to RHI MSM. The random forest model showed that HIV infection biomarkers effectively distinguished between newly diagnosed HIV-infected MSM and HIV-negative MSM, with an ROC AUC of 76.24% (95% CI: 61.17-91.31%).
CONCLUSIONS: MSM showed early intestinal microbiota imbalances after new HIV infection. MSM on ART experienced worsened dysbiosis, indicating a combined effect of HIV and ART. NNRTI-based treatment notably changed intestinal microbiota, suggesting a potential direct impact of NNRTI drugs on intestinal microbiota.
PURPOSE: An orient herbal medicinal formulation for the treatment of diabetes is provided. The formulation has especially curative and preventive effect for the insulin non-dependent diabetes(type 2 diabetes) and its complication as well as insulin dependent diabetes(type 1 diabetes) by lowering sugar content in the body. It also has excellent effect as a toner for the weak liver, kidney, stomach, lung and heart and as body stamina. CONSTITUTION: The formulation comprises: Euonymus alatus (Thumb) Sieb; balsam pear; Lycium root; corn filament; Salviae Radix; white Atractylis; Curcuma longa Rhizoma; white agaric; Alisma; Cuscuta seed; root peel of Paeonia moutan Sims in a weight ratio of 30: 10: 10: 10: 5: 5: 5: 7: 5: 5: 3, respectively. The cleaned Euonymus alatus (Thumb) Sieb is put into distilled water and the solution is made pH9 by adding NaOH, boiled under pressure for 3 hours, filtered, concentrated, dried under vacuum, ground and made powder by screening more than 100 times. The cleaned corn filament is fermented at 50deg.C(with addition of yeast), separated from unwanted material, boiled under pressure with distilled water of 5 times for 3 hours, filtered, concentrated, dried under vacuum and made powder by screening more than 100 times. Salviae Radix is extracted with 70% ethanol, concentrated and dried under vacuum and made powder by screening more than 100 times. Lycium root, white Atractylis, Curcuma longa Rhizoma, white agaric, Alisma and Cuscuta seed and root peel of Paeonia moutan Sims are mixed, distilled water of 5 times is added, boiled 3 hours under vacuum, concentrated and dried under vacuum and made powder by screening more than 100 times. Balsam pear is obtained in liquid after freeze extracting and concentrating the filtrate. The above powders are mixed, screened more than 100 times, added to the concentrate of balsam pear and freeze dried to make the final formulation.
Mucormycosis, a group of opportunistic mycoses caused by Mucorales, present a significant threat to immunocompromised patients. In this report, we present the case of a 57-year-old male patient who underwent liver transplant for secondary biliary cirrhosis following inadvertent bile duct injury. Despite initial satisfactory postoperative evolution, the patient developed fever, and imaging revealed a suspicious lesion. Preliminary culture growth suggested a filamentous fungus, leading to initiation of liposomal amphotericin B. However, the lesion progressed, and a surgical debridement was necessary. During surgery, involvement of the liver dome and diaphragm was observed, and a nonanatomical hepatectomy was performed. Despite efforts, the patient's condition deteriorated, ultimately resulting in multiple organ failure and mortality. This case emphasizes the challenging nature of mucormycosis in livertransplant recipients.